These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 6139329)

  • 21. Bromocriptine acute effect on insulin, glucagon and growth hormone levels in acromegalic patients.
    Fedele D; Molinari M; Meneghel A; Valerio A; Muggeo M; Tiengo A
    J Endocrinol Invest; 1980; 3(2):149-53. PubMed ID: 6993548
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The antidiabetic action of somatostatin-28 as assessed by the artificial endocrine pancreas: greater potency than somatostatin-14.
    Hadjidakis DI; Raptis SA; Raptis AE; Karaiskos C; Souvatzoglou A; Diamantopoulos EJ
    Horm Metab Res; 1987 Nov; 19(11):574-8. PubMed ID: 2892770
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men.
    Gonzalez-Barcena D; Mendoza F; Medina R; Coy DH; Murphy WA; Schally AV
    Endocr Res; 1984; 10(1):39-48. PubMed ID: 6146518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Somatostatin, insulin and glucagon after arginine stimulation in active and treated acromegaly.
    Skare S; Kriz V; Hanssen KF
    Acta Endocrinol (Copenh); 1986 Feb; 111(2):145-50. PubMed ID: 2869632
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly.
    Plewe G; Beyer J; Krause U; Neufeld M; del Pozo E
    Lancet; 1984 Oct; 2(8406):782-4. PubMed ID: 6148524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-response study of the inhibiting effect of somatostatin on growth hormone and insulin secretion in normal subjects and acromegalic patients.
    Giustina G; Peracchi M; Reschini E; Panerai E; Pinto M
    Metabolism; 1975 Jul; 24(7):807-15. PubMed ID: 1138156
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of growth hormone and glucagon release by Phe-4-somatostatin in patients with acromegaly.
    Charro AL; Cabranes JA; Lafuente A; Diaz-Salgado C; Cordero M; Almoguera I; Comaru-Schally AM; Meyers CA; Coy DH; Schally AV
    Res Commun Chem Pathol Pharmacol; 1984 Sep; 45(3):432-44. PubMed ID: 6150529
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The effect of somatostatin on plasma insulin and growth hormone levels in basal conditions and after glucagon in normal and acromegalic subjects.
    Massara F; Porzio G; Camanni F; Molinatti GM
    Acta Diabetol Lat; 1975; 12(3-4):219-31. PubMed ID: 1224905
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Non-selective inhibition of basal glucagon release by [D-Cys14]-analogues of somatostatin in the rat.
    Märki F; Kamber B; Rink H; Sieber P
    J Endocrinol; 1979 Jun; 81(3):315-23. PubMed ID: 469462
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of somatostatin on established induced ketosis.
    Fallucca F; Barbetti F; Maldonato A; Spallone V; Giangrande L; Gambardella S
    Horm Metab Res; 1982 Oct; 14(10):512-5. PubMed ID: 6129185
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a long acting glucagon selective somatostatin analogue on plasma glucose, insulin and glucagon levels in the anaesthetized rat during arginine infusion.
    Lien E; Sarantakis D
    Diabetologia; 1979 Jul; 17(1):59-64. PubMed ID: 467854
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of high dose somatostatin analogue on growth hormone concentrations in acromegaly.
    Sandler LM; Burrin JM; Joplin GF; Bloom SR
    Br Med J (Clin Res Ed); 1988 Mar; 296(6624):751-2. PubMed ID: 2894886
    [No Abstract]   [Full Text] [Related]  

  • 33. Effect of somatostatin and a glucagon-specific analog on glucose homeostasis during arginine infusion.
    Lien EL
    Metabolism; 1978 Sep; 27(9):1095-100. PubMed ID: 682972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biological activity of somatostatin and somatostatin analogs on inhibtion of arginine-induced insulin and glucagon release in the rat.
    Brown M; Rivier J; Vale W
    Endocrinology; 1976 Feb; 98(2):336-43. PubMed ID: 813991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of somatostatin on hormonal and metabolic responses in chronic pancreatitis.
    Botha JL; Vinik AI; le Roith D; Child PT; Jackson WP
    S Afr Med J; 1977 Jun; 51(24):872-5. PubMed ID: 897837
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prolonged suppression of insulin release by a somatostatin analog.
    Lien EL; Garsky VM
    Endocrinology; 1978 Jul; 103(1):81-5. PubMed ID: 744088
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Plasma glucagon and insulin concentrations in acromegaly.
    Trimble ER; Atkinson AB; Buchanan KD; Hadden DR
    J Clin Endocrinol Metab; 1980 Sep; 51(3):626-31. PubMed ID: 6997331
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The inhibitory effect of somatostatin on growth hormone, insulin and glucagon secretion in diabetes mellitus.
    Ward FR; Leblanc H; Yen SS
    J Clin Endocrinol Metab; 1975 Sep; 41(3):527-32. PubMed ID: 1159060
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Growth hormone modulation of arginine-induced glucagon release: studies of isolated growth hormone deficiency and acromegaly.
    Seino Y; Taminato T; Goto Y; Inoue Y; Kadowaki S; Hattori M; Mori K; Kato Y; Matsukura S; Imura H
    Clin Endocrinol (Oxf); 1978 Dec; 9(6):563-70. PubMed ID: 747897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subcutaneous administration of somatostatin analogs as a major factor in the enhancement of the duration of action.
    Torchiana ML; Cook PG; Wiese SR; Saperstein R; Veber DF
    Arch Int Pharmacodyn Ther; 1978 Sep; 235(1):170-6. PubMed ID: 736688
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.